PerkinElmer, Inc.

745 articles with PerkinElmer, Inc.

• PerkinElmer Board Declares Quarterly Dividend - Apr 29, 2021

  4/29/2021

  The Board of Directors of PerkinElmer, Inc., declared a regular quarterly dividend of $0.07 per share of common stock April 29, 2021.

• PerkinElmer to Present at BofA Securities 2021 Virtual Health Care Conference

  4/21/2021

  PerkinElmer, Inc. (NYSE: PKI), a global leader committed to innovating for a healthier world, today announced that the Company will present at the BofA Securities 2021 Virtual Health Care Conference on Wednesday, May 12, 2021 at 9:30 a.m. ET.

•  PerkinElmer Provides First Quarter Update and Schedules Earnings Call for Tuesday, May 4, 2021

  4/13/2021

  PerkinElmer, Inc. (NYSE: PKI), a global leader committed to innovating for a healthier world, today announced that it anticipates reported and organic revenue growth of 98% and 90%, respectively, for the first quarter ended April 4, 2021.

• PerkinElmer Launches Industry-First CRM Reagent and Consumable Kit to Streamline Cannabis Pesticide Testing Workflows

  3/18/2021

  PerkinElmer, Inc. , a global leader committed to innovating for a healthier world, today launched its ONE Pesticide 420 ™ CRM Reagent and Consumable Kit for cannabis & hemp testing. Initially the kits will support pesticide and mycotoxin testing

• PerkinElmer Further Expands Industry-Leading Signals™ Informatics Capabilities in Biologics Drug Discovery

  3/17/2021

  PerkinElmer, Inc., a global leader committed to innovating for a healthier world, today announced its industry-leading documentation, workflow and decision making Signals™ informatics platform is being expanded to build on existing capabilities in the biologics drug discovery space.

• PerkinElmer Completes Acquisition of Oxford Immunotec Global PLC

  3/9/2021

  PerkinElmer, Inc. , (NYSE: PKI) a global leader committed to innovating for a healthier world, today announced that the Company has completed its previously announced acquisition of Oxford Immunotec Global PLC (Oxford Immunotec). PerkinElmer originally announced its intent to acquire Oxford Immunotec on January 7, 2021. “Oxford Immunotec’s global role in fighting tuberculosis, particularly its trademark product,

• PerkinElmer Adds HPLC Columns to Consumables Portfolio

  3/8/2021

  PerkinElmer, Inc ., a global leader committed to innovating for a healthier world, today announced that it has added state-of-the-art columns and chemistries to its LC consumables portfolio by acquiring ES Industries , based in West Berlin, New Jersey in the U.S.

• PerkinElmer Prices Offering of Senior Notes - Mar 05, 2021

  3/5/2021

  PerkinElmer, Inc., a global leader committed to innovating for a healthier world, announced that it has priced an offering of $400.0 million aggregate principal amount of 2.550% Senior Notes due 2031 at an issue price of 99.965% of the principal amount and $400.0 million aggregate principal amount of 3.625% Senior Notes due 2051 at an issue price of 99.999% of the principal amount.

• PerkinElmer Changes COVID-19 Rapid Testing Landscape with Highly Sensitive Point of Care Antigen Test for Mass Screening

  2/23/2021

  Company expands portfolio of SARS-CoV-2 testing solutions with rapid antigen test benchmarked against gold standard RT-PCR

• PerkinElmer Provides an Update on Valencia Branch Laboratory’s Accreditation Process

  2/22/2021

  PerkinElmer, Inc., (NYSE: PKI) a global leader committed to innovating for a healthier world, today provided an update on the COVID-19 Valencia Branch Laboratory’s (VBL) accreditation process.

• PerkinElmer Launches First Cell Painting Kit

  2/16/2021

  New PhenoVue™ cell painting reagent kit makes the process of “painting” cells easier for research scientists by providing carefully selected and pre-optimized reagents

• PerkinElmer to Present at Cowen Health Care Conference

  2/16/2021

  PerkinElmer, Inc. (NYSE: PKI), a global leader committed to innovating for a healthier world, today announced that the Company will present at the 41 st Annual Cowen Health Care Conference on Monday, March 1, 2021 from 12:20 p.m. to 12:50 p.m. ET.

• PerkinElmer Announces Financial Results for the Fourth Quarter and Full Year of 2020

  2/2/2021

  4Q Revenue of $1.355 billion; 68% reported growth; 65% organic growth 4Q GAAP EPS from continuing operations of $3.38; Adjusted EPS of $3.96 Initiates First Quarter and Full Year 2021 Guidance

• PerkinElmer Board Declares Quarterly Dividend - Jan 28, 2021

  1/28/2021

  The Board of Directors of PerkinElmer, Inc., declared a regular quarterly dividend of $0.07 per share of common stock January 28, 2021.

• PerkinElmer Launches Industry-First GPCR TR-FRET Binding Assay and Beta-Arrestin Kits to Help Advance Therapeutics Discovery

  1/26/2021

  New offerings join PerkinElmer’s leading GPCR Portfolio across characterization and screening assays, screening libraries and workflow optimization

• PerkinElmer SARS-CoV-2 RT-PCR Assay Receives FDA EUA for Asymptomatic Testing

  1/14/2021

  PerkinElmer, Inc. (NYSE:PKI) announced today that its PerkinElmer ® New Coronavirus Nucleic Acid Detection Kit received Emergency Use Authorization (EUA) from the U.S. Food and Drug Administration (FDA) to test individuals without symptoms or other reasons to suspect COVID-19 infection. According to a new model f

• EUROIMMUN Launches SARS-CoV-2 Test System to Detect T-Cell Response

  1/14/2021

  Novel test supports vaccine development studies critical to aiding researchers in understanding immunity levels and disease progression

• PerkinElmer Updates Fourth Quarter Outlook; To Hold Earnings Call on Tuesday, February 2, 2021

  1/11/2021

  PerkinElmer, Inc., a global leader committed to innovating for a healthier world, announced that it anticipates reported and organic revenue growth of approximately 66% and 63%, respectively, GAAP earnings per share from continuing operations of at least $2.88, and adjusted earnings per share from continuing operations of at least $3.60 for the fourth quarter ended January 3, 2021.

• PerkinElmer to Present at J.P. Morgan Healthcare Conference - Dec 16, 2020

  12/16/2020

  PerkinElmer, Inc., a global leader committed to innovating for a healthier world, announced that the Company will present at the annual J.P. Morgan Healthcare Conference on Monday, January 11, 2021 at 7:30 a.m. ET.

• Charnwood Lighthouse Lab Goes Live Processing Thousands of COVID-19 Tests per Day with PerkinElmer Solutions

  11/30/2020

  UK’s newest Lighthouse Lab boosts the country’s COVID-19 testing capacity, while generating hundreds of new local jobs